C4 glomerulopathy overview

Revision as of 04:19, 8 August 2020 by Norina Usman (talk | contribs)
Jump to navigation Jump to search

C4 glomerulopathy Microchapters

Complement Mediated Glomerular Disorders Main Page

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating C4 glomerulopathy from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

X ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Studies

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

C4 glomerulopathy overview On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of C4 glomerulopathy overview

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on C4 glomerulopathy overview

CDC on C4 glomerulopathy overview

C4 glomerulopathy overview in the news

Blogs on C4 glomerulopathy overview

Directions to Hospitals Treating C4 glomerulopathy

Risk calculators and risk factors for C4 glomerulopathy overview

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Ali Poyan Mehr, M.D. [2]; Associate Editor(s)-in-Chief: Olufunmilola Olubukola M.D.[3]

Overview

Historical Perspective

There is limited information about the historical perspective of C4 glomerulopathy.

Classification

C4 glomerulopathy may be classified based on complement deposition into Dense Deposit Disease (DDD) and C4 Glomerulonephritis (C4GN)

Pathophysiology

It is thought that C4 glomerulopathy is the result of the activation of immune complex glomerulonephritis or lectin pathway of the complement.

Differential Diagnosis

C4 glomerulopathy must be differentiated from other diseases that cause proteinuria, hematuria, and peripheral edema, such as IgA nephropathy, membranous nephropathy, focal segmental glomerulus /minimal change disease, membranoproliferative glomerulonephritis, and lupus nephritis.

Causes

C4 glomerulopathy may be caused by mutation of complement factor,anti-factor H, anti-factor B, or C4 nephritic factor.

Risk Factors

There are no established risk factors for C4 glomerulopathy.

Screening

There is insufficient information to recommend routine screening for C4 glomerulopathy.

Epidemiology and Demographics

There is not much information available about the incidence and prevalence.

Natural History, Complications, and Prognosis

If left untreated, C4 glomerulopathy may progress to develop renal failure.

Diagnosis

History and Symptoms

The most common symptoms of C4 glomerulopathy include hematuria, proteinuria, and hypertension.

Physical Examination

Physical examination of patients with C4 glomerulopathy is usually remarkable for high blood pressure, peripheral edema, pale skin, and periorbital edema.

Laboratory Findings

Laboratory findings consistent with the diagnosis of C4 glomerulopathy include abnormal urinalysis, abnormal BUN: Creatinine ratio, and abnormal serum C3 and C4 levels

Imaging Studies

There are no other imaging findings associated with C4 glomerulopathy.

Other Diagnostic Studies

A kidney biopsy may be helpful in the diagnosis of C4 glomerulopathy. Findings diagnostic of C4 glomerulopathy include glomerular capillary walls thickening, large subendothelial osmiophilic dense deposits, and ribbonlike material on the glomerular basement membrane.

Treatment

Medical Therapy

The mainstay of treatment for C4 glomerulopathy is antihypertensive and lipid-lowering drugs.

Surgery

Surgical intervention is not recommended for the management of C4 glomerulopathy.

Prevention

There are no established measures for the primary or secondary prevention of C4 glomerulopathy.


References

Template:WHTemplate:WS